SCHEMBL30447196

SCHEMBL30447196

COC[C@H](C(=O)OCc1ccccc1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.55
ALDH1A1 P00352 4/20 0.54
GAA P10253 2/20 0.54
HSD11B1 P28845 1/20 0.53
POLB P06746 4/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30447792 0.85 ALDH1A1 (0.45) HTTALDH1A1L3MBTL1KMT2ACYP3A4
SCHEMBL25640385 0.85 ALDH1A1 (0.45) HTTALDH1A1L3MBTL1KMT2ACYP3A4
SCHEMBL14681023 0.84 ALDH1A1 (0.49) HTTALDH1A1GAAHSD11B1POLB
SCHEMBL11203228 0.83 ALDH1A1 (0.56) HTTALDH1A1GAAHSD11B1POLB
SCHEMBL25261569 0.83 ALDH1A1 (0.62) ALDH1A1GAAPOLBL3MBTL1KMT2A
SCHEMBL14680989 0.83 ALDH1A1 (0.62) ALDH1A1GAAPOLBL3MBTL1KMT2A
SCHEMBL2481122 0.80 ALDH1A1 (0.52) HTTALDH1A1GAAHSD11B1POLB
SCHEMBL11209614 0.80 ALDH1A1 (0.54) ALDH1A1GAAHSD11B1POLBL3MBTL1
SCHEMBL8655705 0.80 HTT (0.51) HTTALDH1A1GAAHSD11B1POLB
SCHEMBL8655711 0.80 HTT (0.51) HTTALDH1A1GAAHSD11B1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 US disclosed
EP-4444728-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS Pretzel Therapeutics, Inc. (US) 2024-10-16 EP disclosed
WO-2023107487-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 HTT 345/4885ALDH1A1 1527/4885GAA 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.